Overview

Montelukast in Parkinson Disease

Status:
Recruiting
Trial end date:
2025-12-20
Target enrollment:
Participant gender:
Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mostafa Bahaa
Treatments:
Carbidopa
Carbidopa, levodopa drug combination
Levodopa
Montelukast